A Phase 1b/Phase 2a Clinical Study of CWP232291 in Combination with Cytarabine in Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML)
The goal of this clinical research study is to find the recommended dose of the study drug (CWP232291) that can be given in combination with a standard drug (cytarabine) to patients with acute myeloid leukemia (AML) that is either relapsed (disease has come back) or refractory (has not responded to treatment). Researchers also want to learn if the study drug combination can help to control the disease. The safety of the drug combination will also be studied.
Treatment Location: N/A
IRB Review and Approval Date: 09/22/2017
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: